A Study to Learn About Study Medicine Called PF-07261271 in Healthy People

An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the last follow-up date, were considered as TEAEs. AEs included all SAEs and Non-SAEs.

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a TEAE if the event started during the effective duration of treatment. All events that started on or after the first dosing day and time/start time, if collected, but before the end of the last follow-up date, were considered as TEAEs. AEs included all SAEs and Non-SAEs.

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAEs were defined as any untoward medical occurrence that, at any dose, met one or more of the criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or other medically significant event.

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAEs were defined as any untoward medical occurrence that, at any dose, met one or more of the criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or other medically significant event.

Criteria for abnormal values of vital signs: systolic blood pressure (millimeters of mercury [mmHg]) value less than (<) 90 mmHg, change greater than or equal to (>=) 30 mmHg increase, change >= 30 mmHg decrease; diastolic blood pressure (mmHg), value <50 mmHg, change >=20 mmHg increase, change >=20 mmHg decrease; pulse rate (beats per minute [bpm]) value <40bpm, value greater than (>) 120bpm. Clinical significance was determined based on investigator's discretion.

Criteria for abnormal values of vital signs: systolic blood pressure (mmHg) value < 90 mmHg, change >= 30 mmHg increase, change >= 30 mmHg decrease; diastolic blood pressure (mmHg), value <50 mmHg, change >=20 mmHg increase, change >=20 mmHg decrease; pulse rate (bpm) value < 40bpm, value > 120bpm. Clinical significance was determined based on investigator's discretion.

Criteria:Hematology(Activated partial thromboplastin time>1.1*upper limit of normal(ULN); Basophils &eosinophils>1.2*ULN; erythrocytes,hematocrit,hemoglobin,lymphocytes,neutrophils <0.8*lower limit of normal(LLN); leukocytes <0.6*LLN, >1.5*ULN; monocytes >1.2*ULN; platelets <0.5*LLN; prothrombin international randomized ratio &prothrombin Time >1.1*ULN), clinical chemistry (alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase >3.0*ULN; albumin, protein <0.8*LLN, >1.2*ULN; bicarbonate, calcium, chloride, potassium <0.9*LLN,>1.1*ULN; bilirubin >1.5*ULN; creatinine >1.3*ULN; glucose, Glucose-FASTING <0.6*LLN,>1.5*ULN; Sodium <0.95*LLN,>1.05*ULN; Urate: >1.2*ULN;Urea Nitrogen: >1.3*ULN),urinalysis(Bacteria > 20;epithelial cells >=6;granular, hyaline, RBC&WBC casts >1;ketones,leukocyte esterase, nitrite, urine glucose, urine hemoglobin, urine protein>=1,urine erythrocytes,leukocytes >=20;pH(scalar)<4.5,>8.Clinical significance determined on investigator's discretion.

Criteria:Hematology(Activated partial thromboplastin time>1.1*upper limit of normal(ULN); Basophils &eosinophils>1.2*ULN; erythrocytes,hematocrit,hemoglobin,lymphocytes,neutrophils <0.8*lower limit of normal(LLN); leukocytes <0.6*LLN, >1.5*ULN; monocytes >1.2*ULN; platelets <0.5*LLN; prothrombin international randomized ratio &prothrombin Time >1.1*ULN), clinical chemistry (alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase >3.0*ULN; albumin, protein <0.8*LLN, >1.2*ULN; bicarbonate, calcium, chloride, potassium <0.9*LLN,>1.1*ULN; bilirubin >1.5*ULN; creatinine >1.3*ULN; glucose, Glucose-FASTING <0.6*LLN,>1.5*ULN; Sodium <0.95*LLN,>1.05*ULN; Urate: >1.2*ULN;Urea Nitrogen: >1.3*ULN),urinalysis(Bacteria > 20;epithelial cells >=6;granular, hyaline, RBC&WBC casts >1;ketones,leukocyte esterase, nitrite, urine glucose, urine hemoglobin, urine protein>=1,urine erythrocytes,leukocytes >=20;pH(scalar)<4.5,>8.Clinical significance determined on investigator's discretion.

Criteria for abnormal values of ECG parameters: pulse rate (PR) interval greater than or equal to (>=)300 milliseconds (msec); PR interval change >=25 percent (%) or >=50 %, QRS interval >=140 msec and QRS interval change: >=50%. QT interval using Fridericia's correction (QTcF) range from 450 msec to less than (<)480 msec, less than (<) 480 msec to maximum less than or equal to (<=)500 msec, >500 msec, <=30 to <60 msec and >=60 msec. Only rows which included at least 1 participant with abnormality are reported in this outcome measure. Clinical significance was determined based on investigator's discretion.

Criteria for abnormal values of ECG parameters: pulse rate (PR) interval greater than or equal to (>=)300 milliseconds (msec); PR interval change >=25 percent (%) or >=50 %, QRS interval >=140 msec and QRS interval change: >=50%. QT interval using Fridericia's correction (QTcF) range from 450 msec to less than (<)480 msec, less than (<) 480 msec to maximum less than or equal to (<=)500 msec, >500 msec, <=30 to <60 msec and >=60 msec. Only rows which included at least 1 participant with abnormality are reported in this outcome measure. Clinical significance was determined based on investigator's discretion.

AUClast was determined using Linear Log trapezoidal method.

AUCinf was determined as AUClast + (Clast*/kel), where Clast* is the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis.

Cmax was defined as maximum serum concentration.

Tmax was defined as time for Cmax.

t1/2 was determined using Loge (2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log linear -concentration time- curve.

AUCtau was defined as area under the concentration time profile from time zero to time tau (τ), the dosing interval, where tau=672 hours for every 4-week dosing. AUCtau was determined by Linear Log trapezoidal method.

Cmax was defined as maximum serum concentration.

Tmax was defined as time for Cmax.

t1/2 was determined using Loge (2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log linear -concentration time- curve.

ADA positive was defined as ADA titer >= 100; ADA negative defined as ADA titer < 100. Baseline was defined as the last pre-dose measurement

ADA positive defined as ADA titer >= 100; ADA negative defined as ADA titer < 100. Baseline was defined as the last pre-dose measurement.

NAb was determined by electrochemiluminescent (ECL) competitive ligand binding assay using the Meso Scale Discovery (MSD) platform.

NAb was determined by electrochemiluminescent (ECL) competitive ligand binding assay using the Meso Scale Discovery (MSD) platform.